multi-systemic Genetic medicines
Papillon Therapeutics is a clinical stage biotechnology company advancing multi-systemic genetic medicines for diseases with neurologic, cardiac, and other tissue pathologies.
Degenerative diseases impact multiple tissues througout the body, inspiring our unique approach to deliver therapeutic protein to diseased tissues via an innate system within the body.
gene modified stem cells
Papillon Therapeutics leverages gene modified hematopoietic stem and progenitor cell (HSPC) platform technology. Our approach utilizes established clinical procedures and a mature manufacturing industry.
Gene-modified HSPC can differentiate within the body into macrophage, microglia, and other cells that naturally navigate to damaged tissues, including throughout the brain and central nervous system (CNS).
News
2024, APR 15 - NuFund Venture Group Invests in Papillon Therapeutics to Advance Multi-Systemic Genetic Medicines
2023, NOV 20 - UC San Diego Researchers Receive Close to $10M from California Stem Cell Research Agency
2023, AUG 17 - Could stem cell transplants help treat Alzheimer’s disease?
2023, AUG 09 - Stem Cell Therapy Rescues Symptoms of Alzheimer’s Disease
2023, MAY 18 - Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
2022, DEC 01 - Scientists Receive $4.8M to Pursue Gene Therapy for ‘Incurable’ Disease
2019, JUN 20 - CIRM Board Approves New Clinical Trial for Rare Childhood Disease
2016, SEP 21 - Rare, Life-Threatening Childhood Disease is the Focus of CIRM’s Most Recent Investment